Hamlet BioPharma Investor Relations Material
Latest events
Investor Update
Hamlet BioPharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Hamlet BioPharma
Access all reports
Hamlet Pharma AB, a pharmaceutical company, engages in the research and development of cancer drugs. The company's lead product candidate is a patented drug that combines the active ingredient Bisantrene-Guanidinylpenicillamine in a galenic form suitable for oral administration. Its BAR treatment is administered through small pills that slowly release the active ingredient into the upper part of the gastrointestinal tract. The company is headquartered in Malmö, Sweden.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
HAMLET
Country
🇸🇪 Sweden